Green Chemistry in Pharma: How Innovations Are Creating Competitive Advantage?

The pharma industry generates an estimated 25–100 kg of chemical waste per kilogram of active drug produced, and most of that waste is solvent.

It is the starting point for one of the important shifts happening inside pharmaceutical R&D and process chemistry labs today. 

For decades, drug manufacturing tolerated this inefficiency because the science demanded it — complex molecules required harsh reagents, heavy solvents, and energy-intensive batch processes. 

Green chemistry was seen as an idealistic constraint rather than an engineering opportunity.

Now that perception is changing fast.

The global green chemistry market in pharma was valued at $16.5 billion in 2024 and is projected to nearly double to $35 billion by 2033, growing at an annual rate of 10%. 

More importantly, R&D teams at Merck, GSK, and Boehringer Ingelheim are adopting green chemistry for competitive advantages, such as lower manufacturing costs, leaner synthesis routes, and faster regulatory approvals.

​This article breaks down three specific technology breakthroughs and what they signal for the next generation of pharma drug manufacturing.

1. Continuous Flow Technology: From Batch Bottlenecks to Real-Time Production

Continuous manufacturing represents one of the most transformative innovations in pharmaceutical production. Unlike traditional batch processing, which requires days or weeks of downtime between production cycles, continuous flow systems operate without interruption, dramatically reducing production timelines while improving product quality.

Corning’s Advanced-Flow Reactor Platform

Corning Incorporated has built a substantial patent portfolio around continuous-flow reactor technology, with multiple granted patents covering heat-exchange optimization, fluid-connection systems, and process-intensified channel designs. The company’s Advanced-Flow Reactor System 2, launched in June 2023, delivers plug-and-play bench-scale continuous manufacturing with improved temperature control and heat-exchange capabilities.

The technology addresses a critical manufacturing challenge, i.e., heat transfer efficiency. Corning’s silicon carbide and glass-ceramic microchannel modules achieve extremely high surface-area-to-volume ratios, reducing reaction times from minutes to seconds in certain chemistries. 

This translates to lower solvent volumes and higher-concentration operations, directly reducing what the industry calls Process Mass Intensity(PMI)—the total mass of materials required to produce one kilogram of product.

A PMI of 100 means that producing one kilogram of active pharmaceutical ingredient requires 100 kilograms of total input materials (reactants, solvents, catalysts, and reagents).  The median in the pharmaceutical industry ranges from 168 to 308, significantly higher than in other chemical sectors. 

Corning’s flow reactor technology helps companies reduce this ratio by enabling more concentrated reactions with less solvent.

In September 2023, Corning opened an Advanced Flow Pharmaceutical Technology services facility. It provides end-to-end flow process development and scale-up to pharmaceutical companies and CDMOs.

Curia, a major contract development and manufacturing organization, installed Corning’s G1 production system following its March 2023 announcement of a collaboration. The partnership established commercial pathways to scale up bench-scale green chemistries to multi-kilogram production.

Merck’s Keytruda Manufacturing

Merck’s 2024 EPA Green Chemistry Award-winning process for pembrolizumab (Keytruda) demonstrates that continuous manufacturing delivers measurable operational advantages. 

The company replaced large-batch filtration with continuous separation during production, enabling smaller equipment, a reduced facility footprint, and dramatic efficiency gains: 

• 4.5 times lower energy use, 
• 4 times lower water consumption,
• 2-fold reduction in raw materials and consumables.

This process passed regulatory scrutiny, signaling to the industry that continuous manufacturing is no longer experimental and a validated pathway for commercial-scale biologics production.

2. Biocatalysis: Engineering Enzymes for Industrial-Scale Synthesis

Enzymatic synthesis represents a paradigm shift from harsh chemical conditions to mild, selective, and environmentally benign reactions. Recent advances in protein engineering, machine-learning-guided enzyme optimization, and ancestral sequence reconstruction are making biocatalysis practical for previously inaccessible reactions.

Codexis’s Engineered Enzyme Platform

Codexis has developed an extensive patent portfolio covering engineered enzymes for pharmaceutical synthesis, with dozens of granted patents and applications spanning transaminases, hydroxylases, and penicillin acylases. 

These enzymes enable highly stereoselective synthesis of chiral intermediates—critical building blocks for modern pharmaceuticals, where only one mirror-image form of a molecule is therapeutically active.

The company’s ECO Synthesis platform represents a particularly significant innovation for oligonucleotide manufacturing. Traditional solid-phase oligonucleotide chemistry—used for RNA therapeutics and antisense drugs—requires large solvent volumes, multiple protecting-group steps, and generates substantial chemical waste. 

In 2023, Codexis’s enzymatic, solution-phase route achieved gram-scale synthesis of modified oligonucleotides under process-like conditions, a critical milestone demonstrating scalability.

This matters because oligonucleotide therapeutics are among the fastest-growing segments in the pharmaceutical industry. As API demand scales to triple-digit kilograms per year, conventional chemical synthesis becomes economically and environmentally unsustainable. 

Enzymatic routes offer the potential to dramatically reduce solvent volumes, reduce or eliminate protecting-group chemistry, and increase atom economy—the percentage of reactant atoms that end up in the final product rather than as waste.

The E-factor provides context for understanding waste reduction. Pharmaceutical manufacturing typically generates E-factors of 25-100, meaning 25 to 100 kilograms of waste per kilogram of product. Enzymatic processes can reduce this substantially because enzymes work at mild temperatures and pressures, use water as a solvent, and achieve high selectivity without generating side-product waste.

GSK and Boehringer Ingelheim Case Studies

GSK’s EPA-recognized second-generation route for mcMMAF (an antibody-drug conjugate payload) achieved a 16,160-kilogram reduction in solvent use per kilogram of product compared to its first-generation process, a 71 percent decrease in greenhouse gas emissions, and a 76 percent reduction in energy consumption. 

Also, the company eliminated all single-use silica-gel chromatography and achieved a 76 percent reduction in PMI.

Boehringer Ingelheim’s three-step asymmetric synthesis of the spiroketone intermediate CD 7659 demonstrates what best-in-class green chemistry can achieve. The new route increased yield from 10 percent to 47 percent, cut organic solvent use by 99 percent, eliminated all halogenated solvents, and reduced water consumption by 76 percent. 

The process achieved a PMI of 117 and a Relative Process Greenness score of 72 percent, placing it in the top 10 percent of all industry processes according to the iGAL metric.

The innovation Green Aspiration Level (iGAL) metric helps R&D teams benchmark their processes against industry standards while accounting for molecular complexity. 

A higher iGAL score means the process is more efficient relative to the complexity of the molecule being synthesized. Boehringer Ingelheim’s “excellent” iGAL rating signals to investors, regulators, and sustainability officers that this represents genuinely innovative green chemistry.

3. Bio-Based Solvents: Securing Sustainable Supply Chains

Solvent selection profoundly impacts the sustainability of pharmaceutical manufacturing. Solvents typically account for 80-90 percent of the total mass in pharmaceutical processes, making them the largest contributor to PMI. 

Bio-based alternatives derived from agricultural waste or renewable feedstocks offer drop-in replacements that reduce lifecycle carbon intensity without requiring process redesign.

2-Methyltetrahydrofuran: Performance and Sustainability Combined

2-Methyltetrahydrofuran (2-MeTHF), derived from furfural, offers superior performance compared to traditional solvents such as THF and dichloromethane: easier phase separation, higher reaction yields in organometallic chemistry, improved stability under acidic and basic conditions, and lower peroxide formation. Suppliers like Penn A Kem and IFC have scaled production and established warehousing to reduce barriers to adoption.

Crucially, because 2-MeTHF comes from agricultural and lignocellulosic waste rather than food crops or petroleum, it addresses the feedstock availability challenge that limits some bio-based materials. This matters for pharmaceutical companies concerned about supply chain resilience and long-term sourcing reliability.

Viridis Chemical: Certified Bio-Based Ethyl Acetate

In March 2022, Viridis Chemical achieved commercial production of 100 percent bio-based ethyl acetate at its Columbus, Nebraska, facility using its proprietary Prairie Green process. The company secured ISCC PLUS and USDA BioPreferred certifications, providing pharmaceutical companies with third-party-validated, regionally produced green solvents.

Ethyl acetate serves as a common extraction solvent in pharmaceutical manufacturing. Having a certified bio-based source with established global distribution (through partnership with HELM AG) provides pharma companies with a credible alternative to fossil-derived solvents. 

Moreover, Viridis received the ICIS 2023 Product Innovation Award, signaling market recognition beyond environmental claims.

However, in January 2026, the company halted its nearly-completed biobased ethyl acetate plant near Peoria, Illinois, primarily due to two compounding pressures. 

First, the biobased chemicals market deteriorated significantly through 2025, weakening investor confidence. 

Second, the plant relocation from Columbus, Nebraska, went over budget and was severely impacted by tariffs. These financial strains led investors, including private equity firm EIV Capital, to call for a halt. Viridis expects a restart in a couple of years, pending new investment.

Strategic Implications for Pharmaceutical R&D

The competitive advantages of green chemistry extend beyond sustainability reporting. Continuous manufacturing reduces time-to-market by eliminating batch-to-batch transfers and enabling faster scale-up. The Novartis-MIT Center for Continuous Manufacturing demonstrated the ability to convert raw materials into tablets in 2 days, compared to 200 days with traditional batch processing.

The technology is moving fast. But most pharma R&D and process chemistry teams still face the same hard questions when they try to act on it:

• Which continuous-flow or biocatalytic route is truly novel, and which space is already crowded with competing patents?
• Where is the white space in bio-based solvent innovation that your pipeline could move into before the window closes?
• How are Merck, GSK, Boehringer Ingelheim, and emerging CDMOs filing their IP in green manufacturing, and what does that signal about where the field is heading?
• Can your existing synthesis route be benchmarked against green chemistry metrics (waste per kg, solvent intensity, process step count) to identify where you’re most exposed?

These are not questions with easy Google answers. They require deep patent landscape analysis, competitive R&D intelligence, and the ability to translate complex chemistry filings into strategic insight.

That’s exactly what we do.

Whether you’re evaluating a new synthetic route, mapping competitor green chemistry IP, or building an internal business case for sustainable manufacturing investment, our team of patent analysts and innovation researchers can give you the intelligence edge you need.